BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/11/2026 7:19:25 AM | Browse: 180 | Download: 612
Publication Name World Journal of Gastroenterology
Manuscript ID 115291
Country China
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Pharmacology & Pharmacy
Manuscript Type Observational Study
Article Title Cost-effectiveness of different strategies with biologics for the treatment of moderate to severe Crohn’s disease in China
Manuscript Source Unsolicited Manuscript
All Author List Yao Wu, Li-Bo Tao, Chang Liu, Fang-Xu Wang, Yi Yan and Shuang Sun
ORCID
Author(s) ORCID Number
Yao Wu http://orcid.org/0009-0001-5919-4757
Li-Bo Tao http://orcid.org/0000-0001-5059-8280
Funding Agency and Grant Number
Corresponding Author Li-Bo Tao, PhD, Senior Researcher, Center for Health Policy and Technology Evaluation, Peking University Health Science Center, No. 38 Xueyuan Road, Haidian District, Beijing 100191, China. taolibo@hsc.pku.edu.cn
Key Words Crohn’s disease; Biologics; Treatment sequence; Cost-effectiveness; China; Outcomes
Core Tip Using a Markov model, this study evaluated the cost-effectiveness of 17 sequential biologic strategies for moderate-to-severe Crohn’s Disease in China. Under a willingness-to-pay threshold of one times the 2024 GDP per capita, the findings suggest that while additional lines of biologic therapy improve health outcomes, they concurrently increase costs. The sequence initiating with adalimumab and followed by ustekinumab emerged as the most cost-effective option, yielding the highest net monetary benefit and a favorable incremental cost-effectiveness ratio for both biologic-naïve and biologic-exposed patients.
Publish Date 2026-02-11 07:19
Citation

Wu Y, Tao LB, Liu C, Wang FX, Yan Y, Sun S. Cost-effectiveness of different strategies with biologics for the treatment of moderate to severe Crohn’s disease in China. World J Gastroenterol 2026; 32(8): 115291

URL https://www.wjgnet.com/1007-9327/full/v32/i8/115291.htm
DOI https://dx.doi.org/10.3748/wjg.v32.i8.115291
Full Article (PDF) WJG-32-115291-with-cover.pdf